Roy S. Herbst, MD, Ph.D., chief of Medical Oncology at Yale University discusses the IASLC 2020 abstract - Lung-Map Translational Discoveries Shared At 2020 World Conference On Lung Cancer.
Link to Article -
To see the full abstracts for these and all WCLC presentations, visit the conference website -
At the 2020 World Conference on Lung Cancer, to be held online January 28-31, 2021, WASHINGTON, DC- Investigators leading the Lung Cancer Master Protocol, or Lung-MAP trial, will present results from three translational medicine studies.
The presentations will mark the first time that researchers will share insights into translational medicine from Lung-MAP, the first large-scale lung cancer precision medicine trial funded by the National Cancer Institute (NCI), part of the National Institutes of Health, and the first major NCI trial to simultaneously test several therapies under one "umbrella" design. The study has tested 12 new therapies for lung cancer since its launch in June 2014. Lung-MAP has also amassed a clinically useful cache of 3,021 patients' data and biospecimens.
At the 2020 World Conference on Lung Cancer or WCLC, the findings from the Lung-MAP studies will be shared. The meeting, organized annually by the International Association for the Study of Lung Cancer, was scheduled for Singapore but will take place digitally due to the pandemic of COVID-19. The WCLC is the largest international meeting of lung cancer and thoracic oncology physicians, doctors, and scientists in the world.
Lung-MAP is a pioneering public-private collaboration that includes the NCI and its National Clinical Trials Network (NCTN), including the SWOG Cancer Research Network, Friends of Cancer Research, the National Institutes of Health Foundation (FNIH), Foundation Medicine, pharmaceutical firms that supplied the study with their products, and other organizations that lobby for lung cancer.
Since the trial is provided under the NCTN and the NCI Community Oncology Research Program (NCORP) at more than 700 U.S. medical centers and community hospitals, Lung-MAP makes it easier for patients to access investigational therapies to combat their non-small cell lung cancer. Lung-MAP is more robust than conventional clinical trial models and quicker. Where conventional trials require individual studies to be established for each new drug studied, a single "master protocol," is used by Lung-MAP, which is updated as drugs enter and leave the study, maintaining facilities and attempts to meet patients. This makes Lung-MAP more effective and cost-effective, allowing the crucial question to be answered quickly by researchers: Does this new drug work?
Lung-MAP has reported more than 3,660 patients since it was launched. Trial leaders, in collaboration with the FNIH, have partnered with 10 pharmaceutical partners to begin 13 trials, 12 of which have been completed. Questions regarding the success of immunotherapy and immunotherapy combinations and the validity of modern biomarkers will be answered in the report. Critical insights into the conduct of large-scale precision medicine studies, including tissue sampling and banking, genetic screening, and patient communication, were also provided by the study.